sub:assertion {
d:DB00507 v:identifier "DB00507" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB00507" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB00507> ;
dv:drugbank-id "APRD00558" , "DB00507" ;
dv:x-atc <
http://bio2rdf.org/atc:P01AX11> ;
dv:x-bindingdb <
http://bio2rdf.org/bindingdb:50182652> ;
dv:x-cas <
http://bio2rdf.org/cas:55981-09-4> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:38037> ;
dv:x-kegg <
http://bio2rdf.org/kegg:D02486> ;
dv:x-ndc <
http://bio2rdf.org/ndc:67546-111-12> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA164754874> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:41684> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:46507813> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Nitazoxanide> ;
dct:description "Nitazoxanide, also known by the brand name Alinia, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1â4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia]"@en ;
dct:identifier "drugbank:DB00507" ;
dct:title "Nitazoxanide"@en ;
a dv:Drug ;
rdfs:label "Nitazoxanide [drugbank:DB00507]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB00507> , <
http://www.drugs.com/cdi/nitazoxanide.html> , <
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ali1659.shtml> , <
http://www.rxlist.com/cgi/generic/alinia.htm> .
}